|
MechanismGABAA receptor agonists [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date03 Jan 2007 |
评价司替戊醇干混悬剂与氯巴占和丙戊酸联合使用治疗Dravet综合征的安全性和有效性的IV期临床研究
[Translation] A phase IV clinical study to evaluate the safety and efficacy of stiripentol dry suspension combined with clobazam and valproic acid in the treatment of Dravet syndrome
通过多中心临床试验研究,评价司替戊醇干混悬剂与氯巴占和丙戊酸联合使用治疗婴儿严重肌阵挛性癫痫(SMEI,Dravet综合征)的安全性和有效性,重点观察可能出现的不良反应,包括不良反应类型、不良反应发生率及不良反应的临床表现及程度。
[Translation] Through multicenter clinical trials, the safety and efficacy of stiripentol dry suspension combined with clobazam and valproic acid in the treatment of severe myoclonic epilepsy of infancy (SMEI, Dravet syndrome) were evaluated, with a focus on possible adverse reactions, including the type of adverse reactions, the incidence of adverse reactions, and the clinical manifestations and severity of adverse reactions.
/ Not yet recruitingPhase 3 Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3
Evaluation of the efficacy and safety of stiripentol in patients 6 years and older with primary hyperoxaluria type 1, 2 or 3.
Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Multiple Oral Administration of Stiripentol 1000 mg in Renal Impaired Patients and Matching Controls With Normal Renal Function
The purpose of this study is to determine whether the pharmacokinetics (PK) of stiripentol and of its relevant metabolites would be altered in subjects with renal impairment compared with normal controls in order to assess the need of dose adjustment in the renal impaired population. This study will include subjects with mild, moderate and severe renal impairment.
100 Clinical Results associated with L-lactate dehydrogenase x GABAA receptor
100 Translational Medicine associated with L-lactate dehydrogenase x GABAA receptor
0 Patents (Medical) associated with L-lactate dehydrogenase x GABAA receptor